Our company is dedicated to accelerating cures for infectious disease
Infectious diseases are the leading cause of deaths worldwide, with the emergence of novel pathogens and the reemergence of drug resistance pathogens threatening to exacerbate this already growing and deadly problem. For this reason, there is an immediate need to develop novel therapeutics against infectious diseases. Antibody-based therapeutics represent one of the most promising forms of highly effective and safe interventions for treating and curing infectious diseases.
Ichor Biologics (Ichor) is a NYC-based, pre-clinical biotechnology company that has gathered a team of highly talented scientists with expertise in Immunology and Infectious Diseases, in order to develop antibody-based therapeutics. Our world-class team has developed a novel, high-throughput platform for the isolation and characterization of naturally occurring human antibodies.
At Ichor Biologics, we are committed to using our expert knowledge and cutting edge technology to provide smarter solutions that we hope will contribute towards a better tomorrow.
What We Do
The Possibilities Are Endless
Smart solutions are at the core of all that we do at Ichor Biologics. Our main goal is finding novel ways to leverage our platform technology to rapidly develop Ab-based therapeutics against the deadliest infectious diseases to help build a better tomorrow for everyone, everywhere. Click below to learn more about the technology behind our platform, or get in touch to set up a meeting with one of our representatives.
Media & Press Updates
Being part of the biotechnology field means we operate in a fast-paced world where changes happen often and quickly. This media section includes all the exciting news and updates about Ichor Biologics. If you have any questions about our articles, please get in touch today.
Ichor develops therapeutic to treat deadly hantavirus infections
In findings published in the November 21st 2018 issue of Science Translational Medicine (Garrido et al.), scientists at Ichor Biologics -- in collaboration with researchers from the NIH and University of Concepción in Chile -- demonstrate that Ichor's two lead antibody-based drugs protect animals against lethal hantavirus infections.
Ichor is awarded $300,000 to develop therapeutics to treat hantavirus infections.
In May 2019, Ichor Biologics received a $300,000 grant from the National Institutes of Health to utilize its platform technology to develop broadly neutralizing antibodies against deadly hantavirus infections.